ARIAD's Ponatinib progressing well in Europe, says RBC Capital RBC Capital's checks indicate ARIAD's Ponatinib EU CHMP recommendation could come as early as the 3rd week of March, putting EU approval at the end of Q2, ahead of guidance for Q3,and that France has used the drug under temporary authorization and has generated $1M + in differed revenues. Shares are Outperform rated.
News For ARIA From The Last 14 Days
Check below for free stories on ARIA the last two weeks.
Subscribe for More Information